Humanized anti-OX40 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9738723-B2
Application number	US-201514877547-A
Country	US
Kind code	B2
Filing date	Oct 7, 2015
Priority date	Oct 10, 2014
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

First claim

What is claimed is:

1. An isolated antibody or fragment thereof comprising a humanized heavy chain variable region (VH) and a humanized light chain variable region (VL);
wherein the VH comprises:
(a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 8,
(b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and
(c) a CDR1 comprising the amino acid sequence of SEQ ID NO: 27,

and wherein the VL comprises:
(d) a CDR1 comprising the amino acid sequence of residues 24-34 of SEQ ID NO: 29,
(e) a CDR2 comprising the amino acid sequence of residues 50-56 of SEQ ID NO: 29, and
(f) a CDR3 comprising the amino acid sequence of residues 89-97 of SEQ ID NO: 29,

wherein the antibody or fragment thereof can specifically bind to human OX40.

2. The antibody or fragment of claim 1 , wherein the antigen-binding fragment is an Fv fragment, an Fab fragment, an F(ab')2 fragment, an Fab' fragment, a dsFv fragment, an scFv fragment, or an sc(Fv)2 fragment, or any combination thereof.

3. The antibody or fragment thereof of claim 1 , which can induce dose-dependent proliferation of activated CD4 + T cells and dose-dependent cytokine release in primary activated human CD4 + T cells in a plate-based assay.

4. The antibody or fragment thereof of claim 3 , wherein a 20% maximal proliferation response (EC 20 ) can be achieved in primary activated human CD4 + T cells at an antibody concentration of about 14 pM to about 28 pM, a 50% maximal proliferation response (EC 50 ) can be achieved in primary activated human CD4 + T cells at an antibody concentration of about 0.3 pM to about 130 pM, and a 90% maximal proliferation response (EC 90 ) can be achieved in primary activated human CD4 + T cells at an antibody concentration of about 50 pM to about 90 pM, all as measured by flow cytometry.

5. The antibody or fragment thereof of claim 4 , wherein EC 20 is about 21 pM, EC 50 is about 28 pM, and EC 90 is about 72 pM.

6. The antibody or fragment thereof of claim 3 , wherein the cytokine is IFNγ, TNFα, IL-5, IL-10, IL-2, IL-4, IL-13, IL-8, IL-12 p70, IL-1β, or any combination thereof.

7. The antibody or fragment thereof of claim 6 wherein the cytokine is IFNγ, TNFα, IL-5, IL-10, IL-13, or any combination thereof.

8. The antibody or fragment thereof of claim 1 , which can achieve CD4 + T cell proliferation and cytokine release in primary activated cynomolgus monkey CD4 + T cells and in primary activated rhesus monkey CD4 + T cells.

9. The antibody or fragment thereof of claim 1 , which can activate the NFκB pathway in OX40 expressing T cells in the presence of FcγR-expressing cells.

10. The antibody or fragment thereof of claim 9 , wherein the OX40-expressing T cells are OX40-expressing Jurkat NFκB-luciferase reporter cells that produce luciferase in response to stimulation of the NFκB signaling pathway.

11. The antibody or fragment thereof of claim 1 , which can trigger complement-dependent or antibody-dependent cellular cytotoxicity against OX40-expressing cells.

12. The antibody or fragment thereof of claim 11 , which can bind to C1q and trigger NK-mediated antibody-dependent cellular cytotoxicity against the OX40-expressing cells.

13. The antibody or fragment thereof of claim 1 , wherein administration of an effective dose to a subject in need of cancer treatment can inhibit tumor growth in the subject.

14. The antibody or fragment thereof of claim 13 , wherein the tumor growth inhibition is achieved in the presence of T cells.

15. The antibody or fragment thereof of claim 13 , wherein tumor growth is inhibited by at least 10%, at least 20%, at least 30%, at least 40%, and least 50%, at least 60%, or at least 70% compared to administration of an isotype-matched control antibody or fragment thereof.

16. A composition comprising the antibody or fragment thereof of claim 1 , and a carrier.

17. An antibody or antigen-binding fragment thereof comprising a humanized heavy chain variable region (VH) and a humanized light chain variable region (VL), wherein the VH comprises the amino acid sequence SEQ ID NO: 59, wherein the VL comprises the amino acid sequence SEQ ID NO: 29, and wherein the antibody or fragment thereof can specifically bind to human OX40.

18. The antibody or fragment thereof of claim 17 comprising the heavy chain amino acid sequence SEQ ID NO: 71 and the light chain amino acid sequence SEQ ID NO: 30.

19. A polynucleotide comprising a nucleic acid that encodes the antibody or fragment thereof, of claim 17 .

20. The polynucleotide of claim 19 , comprising the nucleic acid of SEQ ID NO: 60, the nucleic acid of SEQ ID NO: 31, the nucleic acid of SEQ ID NO: 72, or any combination thereof.

21. A vector comprising the polynucleotide of claim 19 .

22. A host cell comprising the polynucleotide of claim 19 .

23. A method of producing an antibody or fragment thereof, comprising culturing the host cell of claim 22 under conditions in which the antibody or fragment thereof encoded by the polynucleotide is expressed, and recovering the antibody or fragment thereof.

24. A host cell comprising the vector of claim 21 .

Assignees

• Medimmune Llc

Inventors

• Hammond Scott A
• Oberst Michael
• Du Qun
• Damschroder Melissa

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K16/2878 Primary

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• A61K2039/505

  comprising antibodies · CPC title